tgen | Strategic Alliance Partners

November 24, 2020

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

November 19, 2020

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

July 27, 2015

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

May 24, 2014

$12 million in grants pursued by TGen-George Mason Molecular Medicine Alliance, leveraging institutes' expertise in genomics and proteomics.

April 30, 2014

Ramesh K. Ramanathan, MD, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.

December 04, 2013

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.